NCT07483450
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 15 words
- Primary endpoints: details revised at 1 of 3 entries
- Secondary endpoints: details revised at 6 of 18 entries
- Site details revised at 1 of 17 sites
- Notable Primary completion pushed from Mar 12, 2027 to Dec 31, 2027
- Trial status changed: Recruiting → Active, Not Recruiting
- Study completion pushed from Apr 23, 2027 to Dec 31, 2028
- Site details revised at 17 of 17 sites
- Minor Site details revised at 1 of 17 sitesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
RMS Cohort: Annualized Protocol-defined Relapse Rate
Timeframe: Up to approximately 1.6 years
PPMS Cohort: B-cell Levels in Blood
Timeframe: Up to Week 48
PPMS Cohort: Percentage of Participants Achieving Cluster of Differentiation 19 (CD19+) B-cell Levels of <10 Cells/Microliter (μL) at Week 48
Timeframe: At Week 48
Secondary (18)
RMS Cohort: Percentage of Participants Who Have No Evidence of Disease Activity (NEDA3) During a 48-week Period
RMS Cohort: Percentage of Relapse-free Participants by Week 48
RMS Cohort: Percentage of Participants Who Have NEDA3 During a 24-week Period
RMS Cohort: Total Number of T1 Gadolinium (Gd)-enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI)
RMS Cohort: Total Number of New or Enlarging T2 Hyperintense Lesions as Detected by Brain MRI
Show 13 moreShow less
RMS and PPMS Cohorts: Change From Baseline to Week 48 in the Concentration of Serum Neurofilament Light Chain (Nfl)
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
RMS and PPMS Cohorts: Serum Concentration of Ocrelizumab
RMS Cohort: B-cell Levels in Blood
RMS Cohort: Percentage of Participants Achieving CD19+ B-cell Levels of <10 cells/μL at Week 48
PPMS Cohort: Total Number of T1 Gd-enhancing Lesions as Detected by Brain MRI at Week 24 and Week 48
PPMS Cohort: Total Number of New or Enlarging T2 Hyperintense Lesions as Detected by Brain MRI at Week 24 and Week 48
RMS and PPMS Cohorts: Number of Participants With Adverse Events (AEs)
RMS and PPMS Cohorts: Change from Baseline in T-cell Level
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Arms and interventions
RMS CohortExperimental
Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks).
PPMS CohortExperimental
Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks).
Drugs: Ocrelizumab
Sites
17 sites in 1 country